List of 21 COVID-19 related innovations

Welcome to Gavi’s 2019 Annual Progress Report, the fourth in a series of five covering this strategic period.

Building upon two decades of experience in accelerating the availability of billions of doses of vaccines, Gavi is launching an investment opportunity: the Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC).

Since its inception in 2000, Gavi has provided support to 33 Member States of the Organisation of Islamic Cooperation (OIC).

New publication illustrates how the different members of the Vaccine Alliance work together and bring their unique skills and competencies to our public-private partnership.

The Investment Opportunity for the 2021-2025 period highlights the Alliance’s ambition to build on its success by providing the most comprehensive package of protection yet.

The Alliance has played a key role in increasing immunisation coverage across the continent by introducing nine vaccines providing protection against 13 vaccine-preventable diseases.

The 20 year history of an Alliance that today protects half the world’s children.

In this edition of our Annual Progress Report, we look back at the third year of the 2016-2020 strategic period and provide a global context for the work of the Vaccine Alliance.

The Investment Opportunity for the 2021-2025 period highlights the Alliance’s ambition to build on its success by providing the most comprehensive package of protection yet.

Strong supply chains are a critical part of Gavi’s goal to help countries increase the effectiveness and effi ciency of immunisation delivery as an integrated part of health systems.

Gavi, the Vaccine Alliance is committed to ensuring that both boys and girls benefit from life-saving vaccines.

This document is designed to guide country applications for cold chain equipment (CCE) support, providing a structured approach to CCE purchasing decisions. It helps identify which devices comply with the requirements of Gavi's cold chain equipment platform, allowing countries to choose solutions that best meet the needs of their health facilities.

Download this short two-page introduction to the who, what, where and why of Gavi, the Vaccine Alliance.

Immunisation is one of the best buys in global health and key to the achievement of the SDG's.

Immunisation serves as a strong foundation on which to build universal health coverage (UHC). Download this factsheet to learn more about Gavi’s role in strengthening healthcare systems to advance UHC.

Read about Gavi's proven impact over the past 20 years, and the vision for 2021-2025: Prevent, Protect and Prosper.

Published midway through the 2016–2020 reporting period, this 20-page report describes Gavi’s progress in delivering on the Investment Opportunity commitments made at the 2015 Berlin pledging conference as well as how the Alliance is adjusting to its remaining challenges and setting a vision for the future.

High-level, two-page overview of Gavi’s progress in delivering on its Investment Opportunity commitments, adjusting to its remaining challenges and setting out a vision for the future.

Launched at Davos in 2016, Innovation for Uptake, Scale and Equity in Immunisation (INFUSE) seeks tried and tested innovations that have potential to improve vaccine delivery. It then “infuses” them with capital and expertise to help take them to scale.

A two-page overview of Gavi's Mid-Term Review meeting in the United Arab Emirates on 10–11 December 2018.

Evidence-based activities for practitioners, managers and influencers of demand promotion. A guide for discussion facilitators and moderators.

The evidence base for strengthening immunisation demand promotion: tried, tested and novel approaches to engage and motivate communities.

A working session tool for immunisation stakeholders to tailor the evidence base for country plans.

The 2011-2015 period was centered on delivering on the promise of saving children’s lives and protecting people’s health by increasing access to immunisation in the poorest countries.

Biography of Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance.

The innovative Strategic Training Executive Programme (STEP) is helping immunisation supply chain managers across the East African Community to hone their skills and provide more effective supply chain leadership.

Download this factsheet to find out how Gavi and its partners support countries to improve their immunisation supply chains.

Five-page brochure sets out Gavi, the Vaccine Alliance's 2016-2020 strategy, detailing our strategic goals, progress indicators, principles and 'strategic enablers'.

A brochure describing how the Vaccine Alliance works for healthy vaccine markets

The upcoming 2016–2020 strategy period presents a tremendous opportunity to accelerate impact, reach more children with the power of vaccines, and ensure the gains made to date are consolidated and sustained, enabling a healthy future for the next generation. 

The upcoming 2016–2020 strategy period presents a tremendous opportunity to accelerate impact, reach more children with the power of vaccines, and ensure the gains made to date are consolidated and sustained, enabling a healthy future for the next generation.

Thanks to the power of vaccines, more and more children in poor countries are growing up healthier, enabling them to spend more time at school and giving them the chance of a healthy, productive life. The GAVI Alliance exists to redress global inequities in access to new and underused vaccines.

The GAVI Alliance takes stock of progress in reaching its goals halfway through its five-year strategy (2011-2015).

The annual progress report gives a comprehensive overview of the activities and performance of the GAVI Alliance, illustrating the work and achievements of this public-private partnership.

Starting in 2013, GAVI is supporting the poorest countries of the world to roll out two vaccines that will directly benefit women and girls. Vaccinating girls with human papillomavirus vaccines will help protect future generations of women against cervical cancer. Rubella vaccine protects babies from birth defects associated with congenital rubella syndrome, and helps to prevent miscarriage and stillbirth.

GAVI’s mission is to save children’s lives and protect people’s health by increasing access to immunisation in poor countries. To that end, GAVI has become a leading force in the use of innovative finance to fund development initiatives that help GAVI. Learn more in this brochure.

Protecting children’s health through immunisation in the African, Caribbean, and Pacific Group of States

The annual progress report gives a comprehensive overview of the activities and performance of the GAVI Alliance, illustrating the work and achievements of this public-private partnership.

Guidance on how to include gender in health system strengthening funding requests based on national health strategies, using the GAVI-Global Fund joint Funding Request Template

Marking the end of GAVI's first decade, the 2010 Progress Report shows how unprecedented demand, accelerated access to vaccines and strong country ownership have helped save over five million future deaths.

GAVI's 2009 Progress Report paints a picture of developing country commitment and ownership of GAVI programmes. By the end of the year, over 250 million additional children had been vaccinated through GAVI support.

GAVI’s health system strengthening support to Ethiopia is US$ 76,494,000 for 2007 to 2009, and CSO support amounts to US $ 3,420,000 over a two year period from 2008 to 2010. The objectives of the GAVI Alliance for CSO support in Ethiopia are to increase immunisation coverage within seven regions, three of which – Somali, Gambella, and Afar –, have the lowest immunisation rates in the country. The focus of the support will be directed to hard-to-reach and marginalised populations.

US$ 5.41 million have been approved by GAVI for CSO support from 2007 to 2010. The grant was channelled through an already established network of non-governmental organisations (NGOs) that then issued subgrants to other NGOs for

implementation. This has resulted in significant achievements within the first year of implementation.

GAVI’s CSO support to Pakistan amounts to US$ 4,587,000 over a two-year period from 2009 to 2010. The GAVI CSO grant provides an opportunity to improve the partnership between CSOs and the government of Pakistan. CSOs have traditionally

worked with the government on an ad hoc basis, with weak linkages and coordination between the two sectors at both the central and lower levels.

The purpose of these case studies is to document experiences and lessons learned under the GAVI CSO grant, including the application and selection process, implementation to date, and monitoring and reporting.

By the end of 2008, 3.4 million future deaths have been averted through GAVI support for vaccines. In 2008, GAVI undergoes governance and administrative changes, becoming a Swiss international organisation.

2007 was a landmark year for GAVI: it was the initial year of GAVI's first strategic plan; the new health system strengthening programme starts; over 80% of countries eligible for support receive funding for NVS, INS and ISS.

2007 was a landmark year for GAVI: it was the initial year of GAVI's first strategic plan; the new health system strengthening programme starts; over 80% of countries eligible for support receive funding for NVS, INS and ISS.

2007 was a landmark year for GAVI: it was the initial year of GAVI's first strategic plan; the new health system strengthening programme starts; over 80% of countries eligible for support receive funding for NVS, INS and ISS.

In the first five years of GAVI, 15 million more children were reached with basic vaccines, 99 million were reached with new vaccines and 1.2 billion auto-disable syringes were delivered.

After five years in operation, 71 countries out of 75 GAVI-eligible countries have received GAVI support, with one third of resources directed toward strengthening health systems in poorest countries.